RetInSight’s AI algorithms analyze optical coherence tomography (OCT) images captured in routine clinical care to detect and monitor major retinal diseases – geographic atrophy, neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion – which are the leading causes of vision loss globally. These tools enable earlier intervention and personalized treatment planning, especially for aging populations.
“With Topcon Healthcare’s infrastructure, we can scale reliable and affordable AI software globally," said Prof. Hans Peter Schwarz, Chairman of the Board of RetInSight. "This partnership supports clinical care, drug discovery, and therapeutic innovation worldwide."
RetInSight’s platform, born from pioneering research at the Medical University of Vienna, Department of Ophthalmology and Optometry, under the direction of Prof. Dr. Ursula Schmidt-Erfurth, is already commercialized throughout Europe and is vendor-inclusive supporting interoperability across multiple OCT systems.
“RetInSight’s OCT-based AI expertise will help our global network of partners rapidly deploy innovations,” said Ali Tafreshi, CEO & President of Topcon Healthcare, Inc. “Integrated with our Harmony® vendor-inclusive digital information system, we’re delivering clinical decision support and a scalable ecosystem for AI deployment.”
Already used in pharmaceutical trials, RetInSight’s algorithms also support AI-powered drug development and regulatory pathways, including advancing FDA clearances for U.S. indications.
“Together, we’re enabling seamless patient monitoring across the eye care continuum,” said Dr. Amir Sadeghipour, Managing Director of RetInSight. “This collaboration brings intelligent care to patients anywhere.”
This acquisition marks a pivotal step toward global AI adoption in eye care, fostering a connected, developer-friendly ecosystem that drives better outcomes worldwide.
About RetInSight GmbH
RetInSight GmbH, based in Vienna, was founded in 2020 with the ambition that longevity should not come at the expense of vision loss. We aim to enable people to maintain their full vision in order to preserve their quality of life and lifelong autonomy. We are therefore developing transformative AI-based software solutions that leverage routine optical coherence tomography (OCT) images to monitor and detect progressive retinal diseases such as geographic atrophy (GA), neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) – the most important age-related diseases that lead to visual impairments in today’s world. Our mission is to revolutionize ophthalmology through reliable, affordable, and easy-to-use AI-based medical software that enables timely diagnosis, accurate monitoring, and personalized treatment of retinal diseases for anyone, any time and at any location by supporting networked care in ophthalmology with the help of AI technology and digital data. For more info, visit www.retinsight.com
About Topcon Healthcare, Inc.
Topcon Healthcare, Inc. is part of Topcon Corporation, a leading provider of digital healthcare solutions. Our vision is to improve access and quality of healthcare while decreasing the cost of care. To achieve this vision, we created Healthcare from the Eye™, a connected care ecosystem using AI-powered disease detection and management applied to noninvasive retinal imaging. For more information, visit topconhealthcare.com/
Contact
Topcon Healthcare
Leslie Amodei
VP, Marketing for Americas
lamodei@topcon.com
RetInSight GmbH
Klaudia Schuh
Head of Marketing & Communications
klaudia.schuh@retinsight.com